Page 8 - CIMA SCS Workbook November 2018 - Day 1 Tasks

CIMA NOVEMBER 2018 – STRATEGIC CASE STUDY

12. What is the profit margin earned by
Novak on 1 tablet of Mintac?

13. Which projects (in general) might
Novak have difficulty in getting
finance for?

14. What is an “orphan disease”?

15. What is the maximum period of
time for which a pharmaceuticals
company might benefit from
protection to its intellectual
property?

16. What can remain an important
source of competitive advantage to
a pharmaceuticals company once its
product has gone “off-patent”?

17. What enables Novak to attract high
quality research staff?

18. Does Novak manufacture products
developed by other companies that
have gone “off-patent”?

19. By how much has Novak reduced its
carbon emissions from
manufacturing activities over the
last 10 years?

20. How many people does Novak
employ globally?

4 KAPLAN PUBLISHING